Cryptococcus gattii in BC: Update on an emerging disease

Cryptococcus neoformans variety gattii (herein referred to as C. gattii) emerged for the first time in a region with a temperate climate on Vancouver Island, British Columbia, in 1999.[1C. gattii is an environmental fungus that causes infection through inhalation of its spores. In BC, it has been found throughout the east coast of Vancouver Island, where it has been isolated from multiple tree species, soil, water, and air.[2]

Between 1999 and 2006, 176 cases of C. gattii infection were reported among BC residents.[3] Approximately 27 cases were reported every year for an average annual incidence rate of 6.5 cases per million in BC and 27.9 cases per million on Vancouver Island in 2002–06. The mean age of those infected with C. gattii during this period was 59 years (range 2–92 years) and 55% were male. Only two cases occurred in children. The incubation period has been estimated as 6 weeks to 11 months.[4,5

The majority of those infected resided on or traveled to Vancouver Island in the year prior to the onset of symptoms (Figure). Since 2004, six cases of C. gattii infection were reported among BC mainland residents who did not travel to Vancouver Island or other endemic areas in the years prior to onset and are thought to have acquired their infection in the Lower Mainland.[6]

Unlike C. neoformans var. grubii and var. neoformans, C. gattii infects mostly immunocompetent persons. Although C. gattii leads to similar clinical presentations as other varieties, it is less likely to cause disseminated or central nervous system (CNS) disease but more likely to form cryptococcomas.[7]

Most BC C. gattii patients present with pulmonary infection. Common presenting symptoms include cough, dyspnea, chest pain, and weight loss. Some individuals with pulmonary infection are asymptomatic. Radiological findings include lung cryptococcomas, infiltrates, and cavitary lesions. Individuals presenting with CNS infection most often have meningitis with or without brain cryptococcomas. Common symptoms include headache, fever, night sweats, and weight loss. To date, eight people have died of cryptococcosis (case fatality rate = 4.5%).

Serum antigen detection, microscopy of respiratory or cerebrospinal fluid (CSF), and histopathology of affected tissue sites can provisionally diagnose Cryptococcus infection. Only evaluation of cultured isolates can confirm infection with C. gattii. In BC, all suspect isolates of C. gattii are confirmed by genotyping at the BCCDC laboratory. The most appropriate diagnostic specimens for culture are bronchial washings and CSF. 

Imaging often reveals single or multiple chest or head masses, which may be misdiagnosed as malignancy. During biopsy of these masses, a portion of the specimen should be sent to a bacteriology laboratory for culture as histopathologic investigation is insufficient to confirm C. gattii infection.

As Cryptococcus infection has been reportable in BC since 2003, all Cryptococcus cases should be reported to the local public health authority for follow-up.

The Infectious Diseases Society of America has published clinical practice guidelines for the management of cryptococcal disease.[8] However, specific guidelines for the management of C. gattii infection have not been developed. Due to slower responses, more frequent clinical relapses, and more neurologic sequelae, clinicians tend to treat C. gattii infection more aggressively than C. neoformans. Referral to a respirologist or infectious disease specialist for treatment is recommended.

It is unclear why C. gattii emerged on Vancouver Island in the late 1990s. Although C. gattii infection remains rare, it can have serious outcomes. Rapid diagnosis and treatment as well as reporting of the disease to public health authorities will help monitor spread and better understand this emerging disease.

For more information on C. gattii in BC, visit www.bccdc.org and www.cryptococcusgattii.ca.

Acknowledgments
We thank Mr Sunny Mak, Dr Mohammad Morshed, Dr Karen Bartlett, and BC physicians, lab personnel, environmental health officers, and medical health officers for their contributions.

Eleni Galanis, MD
Shannon Waters, MD
Min Li, BSc
Linda Hoang, MD
Laura MacDougall, MSc
Peter Phillips, MD

Dr Galanis, Dr Waters, Mr Li, Dr Hoang, and Ms MacDougall are with the BC Centre for Disease Control. Dr Waters is also with the Community Medicine Residency Program, University of British Columbia, and Dr Phillips is with the Division of Infectious Diseases, St. Paul’s Hospital, BC.


References

1. Stephen C, Lester S, Black W, et al. Multispecies outbreak of cryptococcosis on southern Vancouver Island, British Columbia. Can Vet J 2002;43:792-794.
2. Kidd SE, Chow Y, Mak S, et al. Characterization of environmental sources of the human and animal pathogen, Cryptococcus gattii in British Columbia, Canada, and the Pacific Northwest USA. Appl Environ Microbiol 2007;73:1433-1443.
3. BC Centre for Disease Control. BC Cryptococcus gattii Surveillance Summary, 1999-2006. 2007. www.bccdc.org/topic.php?item=109 (accessed 1 August 2007).
4. MacDougall L, Fyfe M. Emergence of Cryptococcus gattii in a novel environment provides clues to its incubation period. J Clin Microbiol 2006;44:1851-1852.
5. Lindberg J, Hagen F, Laursen A, et al. Cryptococcus gattii risk for tourists visiting Vancouver Island, Canada. Emerg Infect Dis 2007;13:178-179.
6. MacDougall L, Kidd S, Galanis E, et al. Spread of Cryptococcus gattii in British Columbia, Canada and its detection in the Pacific Northwest, USA. Emerg Infect Dis 2007;13:42-50.
7. Perfect JR, Casadevall A. Cryptococcosis. Infect Dis Clin North Am 2002;16:837-874.
8. Saag MS, Graybill RJ, Larsen RA, et al. Practice guidelines for the management of cryptococcal disease. Clin Infect Dis 2000;30:710-718.

Eleni Galanis, MD, MPH, FRCPC, Shannon Waters, MD,, Min Li, BSc,, Linda M.N. Hoang, MD, MHSc, FRCPC, Laura MacDougall, MSc, Peter Phillips, MD,. Cryptococcus gattii in BC: Update on an emerging disease. BCMJ, Vol. 49, No. 7, September, 2007, Page(s) 374-375 - BCCDC.



Above is the information needed to cite this article in your paper or presentation. The International Committee of Medical Journal Editors (ICMJE) recommends the following citation style, which is the now nearly universally accepted citation style for scientific papers:
Halpern SD, Ubel PA, Caplan AL, Marion DW, Palmer AM, Schiding JK, et al. Solid-organ transplantation in HIV-infected patients. N Engl J Med. 2002;347:284-7.

About the ICMJE and citation styles

The ICMJE is small group of editors of general medical journals who first met informally in Vancouver, British Columbia, in 1978 to establish guidelines for the format of manuscripts submitted to their journals. The group became known as the Vancouver Group. Its requirements for manuscripts, including formats for bibliographic references developed by the U.S. National Library of Medicine (NLM), were first published in 1979. The Vancouver Group expanded and evolved into the International Committee of Medical Journal Editors (ICMJE), which meets annually. The ICMJE created the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals to help authors and editors create and distribute accurate, clear, easily accessible reports of biomedical studies.

An alternate version of ICMJE style is to additionally list the month an issue number, but since most journals use continuous pagination, the shorter form provides sufficient information to locate the reference. The NLM now lists all authors.

BCMJ standard citation style is a slight modification of the ICMJE/NLM style, as follows:

  • Only the first three authors are listed, followed by "et al."
  • There is no period after the journal name.
  • Page numbers are not abbreviated.


For more information on the ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals, visit www.icmje.org

BCMJ Guidelines for Authors

Leave a Reply